To identify enantioselective nonsteroidal aromatase inhibitors, a multidisciplinary medicinal chemistry approach was pursued. First, our earlier CoMFA model [Bioorg. Med. Chem. 1998,6, 377-388] was extended taking purposely into account previously discovered enantioselective aromatase inhibitors. The 3D QSAR model was then exploited to design chiral ligands, whose configurational assignment was obtained, after HPLC separation, by means of a combination of circular dichroism measurements and time dependent density functional calculations. Finally, the new enantiomeric inhibitors were separately tested to ascertain both their potency against the cytochrome P450 aromatase (CYP19; EC 1.14.14.1), and their selectivity relative to another enzyme of the P450 family. A satisfactory agreement between experimental and predicted data allowed us to assert that a properly built "enantioselective CoMFA model" might constitute a useful tool for addressing enantioselective ligands design.

Cavalli A., Bisi A., Bertucci C., Rosini C., Paluszcak A., Gobbi S., et al. (2005). Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. JOURNAL OF MEDICINAL CHEMISTRY, 48 (23), 7282-7289 [10.1021/jm058042r].

Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach

CAVALLI, ANDREA;BISI, ALESSANDRA;BERTUCCI, CARLO;GOBBI, SILVIA;RAMPA, ANGELA;BELLUTI, FEDERICA;PIAZZI, LORNA;VALENTI, PIERO;RECANATINI, MAURIZIO
2005

Abstract

To identify enantioselective nonsteroidal aromatase inhibitors, a multidisciplinary medicinal chemistry approach was pursued. First, our earlier CoMFA model [Bioorg. Med. Chem. 1998,6, 377-388] was extended taking purposely into account previously discovered enantioselective aromatase inhibitors. The 3D QSAR model was then exploited to design chiral ligands, whose configurational assignment was obtained, after HPLC separation, by means of a combination of circular dichroism measurements and time dependent density functional calculations. Finally, the new enantiomeric inhibitors were separately tested to ascertain both their potency against the cytochrome P450 aromatase (CYP19; EC 1.14.14.1), and their selectivity relative to another enzyme of the P450 family. A satisfactory agreement between experimental and predicted data allowed us to assert that a properly built "enantioselective CoMFA model" might constitute a useful tool for addressing enantioselective ligands design.
2005
Cavalli A., Bisi A., Bertucci C., Rosini C., Paluszcak A., Gobbi S., et al. (2005). Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. JOURNAL OF MEDICINAL CHEMISTRY, 48 (23), 7282-7289 [10.1021/jm058042r].
Cavalli A.; Bisi A.; Bertucci C.; Rosini C.; Paluszcak A.; Gobbi S.; Giorgio E.; Rampa A.; Belluti F.; Piazzi L.; Valenti P.; Hartmann R.W.; Recanatin...espandi
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/21740
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 64
  • ???jsp.display-item.citation.isi??? 61
social impact